Your browser doesn't support javascript.
loading
Does the menopausal status of female gynecologists affect their prescription of menopausal hormone therapy?
Vallejo, M S; Witis, S; Ojeda, E; Mostajo, D; Morera, F; Meruvia, N; Martino, M; Lima, S; Espinoza, M T; Castillo, O; Campostrini, B; Danckers, L; Blümel, J E; Tserotas, K; Sánchez, H; Salinas, C; Saavedra, J; Rojas, J A; Onatra, W; Monterrosa, A; Montaño, A; Martínez, J; González, E; Gómez, G; Calle, A; Broutin, G; Bencosme, A; Arteaga, E; Ayala, F; Chedraui, P.
Afiliação
  • Vallejo MS; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Witis S; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Ojeda E; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Mostajo D; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Morera F; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Meruvia N; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Martino M; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Lima S; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Espinoza MT; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Castillo O; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Campostrini B; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Danckers L; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Blümel JE; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Tserotas K; b Departamento de Medicina Interna Sur, Facultad de Medicina , Universidad de Chile , Santiago de Chile , Chile ;
  • Sánchez H; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Salinas C; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Saavedra J; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Rojas JA; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Onatra W; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Monterrosa A; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Montaño A; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Martínez J; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • González E; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Gómez G; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Calle A; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Broutin G; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Bencosme A; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Arteaga E; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Ayala F; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
  • Chedraui P; a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
Climacteric ; 19(4): 387-92, 2016 Aug.
Article em En | MEDLINE | ID: mdl-27327136
OBJECTIVE: To evaluate whether menopausal status and symptoms among female gynecologists would influence their clinical behavior related to menopausal hormone therapy (MHT). METHODS: Female gynecologists of 11 Latin American countries were requested to fill out the Menopause Rating Scale and a questionnaire containing personal information and that related to MHT use. RESULTS: A total of 818 gynecologists accepted to participate (86.4%). Overall, the mean age was 45.0 ± 10.7 years, 32.2% were postmenopausal, and 17.6% worked in an academic position; 81.8% reported that they would use MHT if they have symptoms, regardless of menopausal status. Academic gynecologists favor personal MHT use at a higher rate (p = 0.04) and have a higher MHT prescription rate as compared to non-academic ones (p = 0.0001). The same trend was observed among post- as compared to premenopausal ones (p = 0.01) and among those who had hysterectomy alone as compared to those experiencing natural menopause (p = 0.002). The presence of menopausal symptoms did not influence their MHT prescription. Current use of MHT and alternative therapy was higher among post- than premenopausal gynecologists (both, p = 0.0001) and among those who had undergone hysterectomy than those experiencing natural menopause. A 38.5% perceived breast cancer as the main risk related to MHT, and a high proportion prescribed non-hormonal drugs (86.4%) or alternative therapies (84.5%). CONCLUSION: Most female gynecologists in this survey would use MHT if menopausal symptoms were present. Postmenopausal physicians use MHT and prescribe it to their symptomatic patients at a higher rate than premenopausal physicians.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Médicas / Padrões de Prática Médica / Menopausa / Terapia de Reposição de Estrogênios / Ginecologia Tipo de estudo: Qualitative_research Limite: Adult / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Médicas / Padrões de Prática Médica / Menopausa / Terapia de Reposição de Estrogênios / Ginecologia Tipo de estudo: Qualitative_research Limite: Adult / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article